Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

@article{Min2014DipeptidylPI,
  title={Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction},
  author={Hye Sook Min and Jung Eun Kim and M. H. Lee and H. Song and Y. Kang and Mi Jin Lee and J. Lee and Hyun Wook Kim and J. Cha and Y. Y. Chung and Y. Hyun and J. Han and D. Cha},
  journal={Laboratory Investigation},
  year={2014},
  volume={94},
  pages={598-607}
}
Dipeptidyl peptidase IV (DPPIV) is an exopeptidase that modulates the function of several substrates, among which insulin-releasing incretin hormones are the most well known. DPPIV also modulate substrates involved in inflammation, cell migration, and cell differentiation. Although DPPIV is highly expressed in proximal renal tubular cells, the role of DPPIV inhibition in renal disease is not fully understood. For this reason, we investigated the effects of LC15-0444, a DPPIV inhibitor, on renal… Expand
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis
TLDR
Alogliptin exerted renoprotective antifibrotic effects and DPP-4 inhibitors may be promising therapeutic choices even for nondiabetic CKD patients, suggesting an anti-inflammatory action by the D PP-4 inhibitor. Expand
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
TLDR
It is demonstrated that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin. Expand
Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
TLDR
Results indicate that saxagliptin has a potent renoprotective effect in the Dahl-S rats, independent of its glucose-lowering actions, and may contribute to ameliorating renal injury in hypertension-related renal injury. Expand
Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
TLDR
Glomerular and tubular DPP-4 inhibition by saxagliptin was associated with improvements in albuminuria and the suppression of inflammation and fibrosis-related genes and may play an important role in its renoprotective effects in Dahl-S rats. Expand
Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury
TLDR
Data suggest that DPP IV inhibition has an important role in the renoprotection against tacrolimus-induced nephrotoxicity via antioxidative and antiapoptotic effects and preservation of the GLP-1 system. Expand
A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice
TLDR
The results suggest that DPP-4 inhibition by DA-1229 provides renoprotective effects in an animal model of cyclosporine nephrotoxicity via antioxidant, anti-inflammatory, and anti-fibrotic mechanisms. Expand
Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats
TLDR
It is suggested that DPP-4 inhibition can reduce microcirculation lesion-induced renal fibrosis in a GLP-1-dependent manner. Expand
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
TLDR
The present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NOD-like receptor protein 3 (NLRP3) inflammaome activation. Expand
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
TLDR
It is demonstrated that gemigliptin has renoprotective effects on DKD, regardless of its glucose-lowering effect, suggesting that it could be used to preventDKD, including in patients with type 1 diabetes. Expand
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
TLDR
The effects of DPP-4 inhibitors on progressive kidney disease such as diabetic nephropathy is reviewed from a therapeutic point of view and a growing number of studies in animal models and human diseases have shown that D PP-4 inhibition ameliorates kidney disease by a process independent of glucose lowering. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
  • W. Liu, S. Xie, +5 authors T. Park
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 2012
TLDR
The study suggests that DPP IV inhibitors may ameliorate diabetic nephropathy as well as reduce the overproduction of TGF-β1. Expand
DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.
TLDR
Through a mechanism yet to be fully understood, VG treatment results in a functional protection of the kidney against IRI, and was associated with antiapoptotic, immunological, and antioxidative changes. Expand
Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
TLDR
DPP-4 inhibition increases plasma GLP-1 levels, particularly in uremia, and reduces expression of cardiac mRNA levels of matrix proteins and B-type natriuretic peptides (BNP), which may offer a unique approach for treating uremic cardiomyopathy in CKD patients, with no need for dose adjustment. Expand
Ulinastatin inhibits unilateral ureteral obstruction-induced renal interstitial fibrosis in rats via transforming growth factor β (TGF-β)/Smad signalling pathways.
TLDR
The results show that ulinastatin has no statistically significant effect on the BUN and Scr levels (P>0.05), but it can significantly reduce renal interstitial injury and suppress interstitial collagen deposits. Expand
Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.
TLDR
Low circulating CD26 levels in arthritis may influence CD26-mediated regulation of the chemotactic SDF-1/CXCR4 axis, and plasma levels of DPPIV/CD26 from rheumatoid arthritis patients were significantly decreased when compared to those from osteoarthritis patients and inversely correlate with C-reactive protein levels. Expand
Renal and Cardiac Effects of DPP4 Inhibitors – from Preclinical Development to Clinical Research
TLDR
The direct cardiac and renal effects seen in preclinical studies as well as meta-analysis of clinical trials may offer additional potentials – beyond improvement of glycemic control - for this newer class of drugs, such as acute kidney failure, chronic kidney failure as as acute myocardial infarction and heart failure. Expand
Involvement of Dipeptidyl Peptidase IV in Immune Complex–Mediated Glomerulonephritis
TLDR
The results indicate that DPPIV may play a somewhat crucial role in regulating the complement cascade and that inhibition of DPP IV may serve as a new target for preventing complement-dependent tissue injury. Expand
Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
TLDR
Chronic low-dose sitagliptin treatment was able to ameliorate diabetic nephropathy, which might represent a key step forward in the management of T2DM and this serious complication. Expand
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
TLDR
DPP IV appears to be a major physiological regulator for some regulatory peptides, neuropeptides, circulating hormones and chemokines, especially for the insulinotropic hormone GLP-1, which has been tested to enhance insulin secretion and to improve glucose tolerance in diabetic animals. Expand
Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction
TLDR
A link between up-regulation of Ang II/AT1r system and oxidative stress, inflammation, hypertension, and progression of renal disease in rats with renal mass reduction is demonstrated. Expand
...
1
2
3
4
5
...